e-learning
resources
Virtual 2020
Pre-Congress Content
Experimental approaches to pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Soluble LR11 level is correlated with the severity of pulmonary hypertension due to left heart disease.
Y. Joki (Tokyo, Japan), H. Konishi (Tokyo, Japan), K. Takasu (Tokyo, Japan), K. Shimada (Tokyo, Japan)
Source:
Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Session:
Experimental approaches to pulmonary hypertension
Session type:
E-poster session
Number:
1492
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Joki (Tokyo, Japan), H. Konishi (Tokyo, Japan), K. Takasu (Tokyo, Japan), K. Shimada (Tokyo, Japan). Soluble LR11 level is correlated with the severity of pulmonary hypertension due to left heart disease.. 1492
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Under pressure: pulmonary hypertension associated with left heart disease
Source: Eur Respir Rev 2015; 24: 665-673
Year: 2015
Fibrinogen plasma levels and disease severity in pulmonary artery hypertension
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
How to define pulmonary hypertension due to left heart disease
Source: Eur Respir J 2016; 48: 553-555
Year: 2016
Pulmonary hypertension associated with left heart disease
Source: Eur Respir Mon 2012; 57: 119-137
Year: 2012
Pulmonary vascular gradient: A predictor of prognosis in pulmonary hypertension due to left heart disease
Source: Annual Congress 2012 - Pulmonary circulation: end-points and biomarkers
Year: 2012
Does left heart disease cause most systemic sclerosis associated pulmonary hypertension?
Source: Eur Respir J 2013; 42: 888-890
Year: 2013
Serum osteoprotegerin expression correlates with disease progression and severity in rodent models of pulmonary arterial hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Pulmonary hypertension due to left heart disease
Source: Eur Respir J, 53 (1) 1801897; 10.1183/13993003.01897-2018
Year: 2019
Relation between hemodynamics and right ventricular hypertrophy may affect survival and severity of the disease in patients with primary pulmonary hypertension (PPH)
Source: Eur Respir J 2002; 20: Suppl. 38, 26s
Year: 2002
Pulmonary hypertension in left heart disease
Source: Eur Respir Rev 2012 21: 338-346
Year: 2012
Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension and their relationship with right ventricular structure and function
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Prognostic value of right ventricular function in patients with severe pulmonary hypertension associated with respiratory disease
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease
Source: Eur Respir Rev 2011; 20: 236-242
Year: 2011
Pulmonary hypertension associated with left heart disease: efforts to improve the meaning of haemodynamic phenotypes
Source: Eur Respir J, 53 (3) 1802393; 10.1183/13993003.02393-2018
Year: 2019
Pulmonary hypertension associated with left heart disease: efforts to improve the meaning of haemodynamic phenotypes
Source: Eur Respir J, 53 (3) 1801894; 10.1183/13993003.01894-2018
Year: 2019
Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2006; 28: Suppl. 50, 425s
Year: 2006
Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis
Source: Eur Respir J, 51 (4) 1702427; 10.1183/13993003.02427-2017
Year: 2018
How to detect disease progression in pulmonary arterial hypertension
Source: Eur Respir Rev 2012; 21: 40-47
Year: 2012
Usefulness of differential blood gas exchange assessment in patients with severe pulmonary arterial hypertension (PAH) associated to congenital heart disease (CHD)
Source: Eur Respir J 2005; 26: Suppl. 49, 351s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept